Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response.

By B. Moffat, Thomas L. Chenevert, T. Lawrence, Charles R. Meyer, T. Johnson, Q. Dong, C. Tsien, S. Mukherji, D. Quint, S. Gebarski and 4 more. Proceedings of the National Academy of Sciences of the United States of America, 2005

673 citations recorded by the source corpus.

Subfields: Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/c361c5ef55bb5dfe95a2646305f20058fb1ce06a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Radiology, Nuclear Medicine and Imaging

1. B. Taouli
2. Dow-Mu Koh
3. Anwar R. Padhani
4. Joshua D. Trzasko
5. Clifford R. Jack Jr.
6. Thomas L. Chenevert

Citations in the corpus

• Quantitative magnetic resonance imaging phantoms: A review and the need for a system phantom (2018, methodology): “Isotropic diffusion imaging is used as a biomarker to identify tumors and track response to treatments (14,15).”
• Diffusion-weighted MRI in the body: applications and challenges in oncology. (2007, methodology): “Studies in cerebral gliomas [59, 63, 71] and breast carcinoma [72] have also shown that an early increase in the ADC after commencing treatment was predictive of better treatment outcome.”
• Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. (2009, background): “(3) Ideally, to track the spatial origin of changes inducedby treatments, it is necessary to have spatial tags to accurately monitor the change in diffusivity [55,72].”